IBT_B: FDA review of IBP-9414 progresses as losses narrow and launch preparations intensify

About this update from Infant Bacterial Therapeutics Ab Class B

Preparations for the launch of IBP-9414 continue, with FDA review underway and initial feedback expected in September 2025. Operating losses and cash outflows have narrowed year-over-year, and capital is sufficient through the marketing authorization process.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Infant Bacterial Therapeutics Ab Class B